Report copyright - Comment évaluer le bon usage des médicaments innovants ... · Observatoire Cancer B PL 02 2016 . Spécialité AMM PTT Hors AMM Hors PTT/RTU N total ALIMTA® pemetrexed 70,6% 3,6%
Please pass captcha verification before submit form
Please pass captcha verification before submit form